KR20110056537A - Ｃ형 간염의 치료를 위한 화합물 - Google Patents
Ｃ형 간염의 치료를 위한 화합물 Download PDFInfo
- Publication number
- KR20110056537A KR20110056537A KR1020117008086A KR20117008086A KR20110056537A KR 20110056537 A KR20110056537 A KR 20110056537A KR 1020117008086 A KR1020117008086 A KR 1020117008086A KR 20117008086 A KR20117008086 A KR 20117008086A KR 20110056537 A KR20110056537 A KR 20110056537A
- Authority
- KR
- South Korea
- Prior art keywords
- solvent
- alkyl
- phenyl
- fluorophenyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CCCCC(C12C(*)C(CC)C1C2)=C1CCCCC1 Chemical compound CCCCC(C12C(*)C(CC)C1C2)=C1CCCCC1 0.000 description 4
- AVIRHXBXAWDMBS-UHFFFAOYSA-N CC(C)(c1ccccc1)NC(c1cc(-c2cc(c(C(NC)=O)c(-c(cc3)ccc3F)[nH]3)c3nc2)ccc1)=O Chemical compound CC(C)(c1ccccc1)NC(c1cc(-c2cc(c(C(NC)=O)c(-c(cc3)ccc3F)[nH]3)c3nc2)ccc1)=O AVIRHXBXAWDMBS-UHFFFAOYSA-N 0.000 description 1
- YJSHXJLGLMGYGX-UHFFFAOYSA-N CC(C)(c1ccccc1)NC(c1cccc(-c(cc2)cc3c2[nH]c(-c(cc2)ccc2F)c3C(NC)=O)c1)=O Chemical compound CC(C)(c1ccccc1)NC(c1cccc(-c(cc2)cc3c2[nH]c(-c(cc2)ccc2F)c3C(NC)=O)c1)=O YJSHXJLGLMGYGX-UHFFFAOYSA-N 0.000 description 1
- GKVBMXMSRVUIJX-UHFFFAOYSA-N CNC(c1c(-c(cc2)ccc2F)[s]c(cc2)c1cc2-c1cccc(C(O)=O)c1)=O Chemical compound CNC(c1c(-c(cc2)ccc2F)[s]c(cc2)c1cc2-c1cccc(C(O)=O)c1)=O GKVBMXMSRVUIJX-UHFFFAOYSA-N 0.000 description 1
- ZQVXOJPQHNSXMD-UHFFFAOYSA-N CNC(c1c(-c(cc2)ccc2F)[s]c(cc2)c1cc2OC)=O Chemical compound CNC(c1c(-c(cc2)ccc2F)[s]c(cc2)c1cc2OC)=O ZQVXOJPQHNSXMD-UHFFFAOYSA-N 0.000 description 1
- BGIPCUYWHNMDPM-ONEGZZNKSA-N CO/C=C/C(N)=C Chemical compound CO/C=C/C(N)=C BGIPCUYWHNMDPM-ONEGZZNKSA-N 0.000 description 1
- DRIKMFZTUUCFIY-UHFFFAOYSA-N Cc(c(-c1cc2c(C(NC)=O)c(-c(cc3)ccc3F)n[n]2c(F)c1)c1)ccc1C(NC1(CC1)c1ncccc1)=O Chemical compound Cc(c(-c1cc2c(C(NC)=O)c(-c(cc3)ccc3F)n[n]2c(F)c1)c1)ccc1C(NC1(CC1)c1ncccc1)=O DRIKMFZTUUCFIY-UHFFFAOYSA-N 0.000 description 1
- QSUIIMWJOBAZPZ-UHFFFAOYSA-N Cc(c(-c1cc2c(C(NC)=O)c(-c(cc3)ccc3F)n[n]2cc1F)c1)ccc1C(NC1(CC1)c1ccccc1)=O Chemical compound Cc(c(-c1cc2c(C(NC)=O)c(-c(cc3)ccc3F)n[n]2cc1F)c1)ccc1C(NC1(CC1)c1ccccc1)=O QSUIIMWJOBAZPZ-UHFFFAOYSA-N 0.000 description 1
- QSUNBVWETYVQHC-UHFFFAOYSA-N Cc(ccc(C(NC1(CC1)c1ccccn1)=O)c1)c1-c1ncc2[o]c(-c(cc3)ccc3F)c(C(NC)=O)c2c1 Chemical compound Cc(ccc(C(NC1(CC1)c1ccccn1)=O)c1)c1-c1ncc2[o]c(-c(cc3)ccc3F)c(C(NC)=O)c2c1 QSUNBVWETYVQHC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9600408P | 2008-09-11 | 2008-09-11 | |
| US61/096,004 | 2008-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20110056537A true KR20110056537A (ko) | 2011-05-30 |
Family
ID=41203516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117008086A Withdrawn KR20110056537A (ko) | 2008-09-11 | 2009-09-02 | Ｃ형 간염의 치료를 위한 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8198449B2 (OSRAM) |
| EP (1) | EP2331502B1 (OSRAM) |
| JP (1) | JP2012502099A (OSRAM) |
| KR (1) | KR20110056537A (OSRAM) |
| CN (2) | CN102209711B (OSRAM) |
| AR (1) | AR073586A1 (OSRAM) |
| AU (1) | AU2009291993A1 (OSRAM) |
| MX (1) | MX2011002471A (OSRAM) |
| TW (1) | TW201014855A (OSRAM) |
| WO (1) | WO2010030538A2 (OSRAM) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2493889B1 (en) | 2009-10-30 | 2017-09-06 | Janssen Pharmaceutica, N.V. | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| EP2496578A4 (en) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS, THEIR SYNTHESIS AND METHODS OF USE THEREOF |
| FR2953520B1 (fr) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| US8324212B2 (en) * | 2010-02-25 | 2012-12-04 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EP2545050B1 (en) * | 2010-03-10 | 2014-08-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis c |
| US8354410B2 (en) | 2010-03-11 | 2013-01-15 | Bristol-Meyers Squibb Company | Compounds for the treatment of hepatitis C |
| AR082453A1 (es) * | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| US8445497B2 (en) | 2010-06-30 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2012051659A1 (en) * | 2010-10-20 | 2012-04-26 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| SG189985A1 (en) | 2010-10-26 | 2013-06-28 | Presidio Pharmaceuticals Inc | Inhibitors of hepatitis c virus |
| EP2655362A1 (en) | 2010-12-22 | 2013-10-30 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| MX344600B (es) | 2011-06-27 | 2016-12-20 | Janssen Pharmaceutica Nv | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina. |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| US9303020B2 (en) | 2012-02-08 | 2016-04-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EP2831066B1 (en) | 2012-03-27 | 2016-10-05 | Bristol-Myers Squibb Company | Benzofuran derivatives for the treatment of hepatitis c |
| US9120775B2 (en) | 2012-04-11 | 2015-09-01 | Biota Scientific Management Pty Ltd | Viral polymerase inhibitors |
| WO2013163466A1 (en) * | 2012-04-25 | 2013-10-31 | Presidio Pharmaceuticals, Inc. | Inhibitors of hepatitis c virus |
| CN102690264B (zh) * | 2012-06-20 | 2014-07-02 | 泰山医学院 | 2-苯基-3-取代咪唑并[1,2-a]吡啶类衍生物及其制备方法 |
| HK1206250A1 (en) | 2012-06-26 | 2016-01-08 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| CN104411314B (zh) | 2012-07-09 | 2017-10-20 | 詹森药业有限公司 | 磷酸二酯酶10的抑制剂 |
| US8796305B2 (en) | 2012-11-05 | 2014-08-05 | Bayer Pharma Aktiengesellschaft | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8778964B2 (en) | 2012-11-05 | 2014-07-15 | Bayer Pharma Aktiengesellschaft | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use |
| US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US9126998B2 (en) | 2012-11-05 | 2015-09-08 | Bayer Pharma AG | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
| US8871754B2 (en) | 2012-11-19 | 2014-10-28 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| DK2925757T3 (en) | 2012-11-19 | 2018-01-15 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| US8962651B2 (en) * | 2013-03-13 | 2015-02-24 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| ES2625744T3 (es) | 2013-06-04 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Imidazo[1,2-a]piridinas sustituidas con 3-arilo y su uso |
| TW201609651A (zh) * | 2013-11-12 | 2016-03-16 | 陶氏農業科學公司 | 用於氟化化合物之過程（一） |
| CA2939793A1 (en) | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
| AR099820A1 (es) * | 2014-03-21 | 2016-08-17 | Bristol Myers Squibb Co | Ciano que contiene compuestos de azabenzofuran para el tratamiento de la hepatitis c |
| US9920036B2 (en) * | 2014-03-21 | 2018-03-20 | Bristol-Myers Squibb Company | Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C |
| WO2015140199A1 (de) | 2014-03-21 | 2015-09-24 | Bayer Pharma Aktiengesellschaft | Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| EP3137463A1 (de) | 2014-05-02 | 2017-03-08 | Bayer Pharma Aktiengesellschaft | Enantiomere des n-(2-amino-5-fluor-2-methylpentyl)-8-[(2,6-difluorbenzyl)oxy]-2-methylimidazo[1,2-a]pyridin-3-carboxamids sowie der di- and tri-fluor-derivate zur behandlung von kardiovaskulären erkrankungen |
| EP3180346A1 (en) * | 2014-08-05 | 2017-06-21 | Bristol-Myers Squibb Company | Furopyridine compounds for the treatment of hepatitis c |
| WO2016045587A1 (zh) | 2014-09-26 | 2016-03-31 | 常州寅盛药业有限公司 | 作为ns4b抑制剂的苯并呋喃类似物 |
| EP3227287B1 (de) | 2014-12-02 | 2019-08-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituierte imidazo[1,2-a]pyridine und ihre verwendung |
| AU2016324598A1 (en) | 2015-09-17 | 2018-03-15 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| WO2018184976A1 (de) | 2017-04-05 | 2018-10-11 | Bayer Pharma Aktiengesellschaft | Substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung |
| RU2019123849A (ru) | 2019-07-29 | 2021-02-01 | Дзе Брихэм Энд Уимен`З Хоспитал, Инк. | Ингибиторы фактора ингибирования миграции макрофагов |
| WO2024102699A1 (en) * | 2022-11-07 | 2024-05-16 | ELANCO US, Inc. | Guanylate cyclase (gc) stimulator formulations and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3502707A (en) * | 1967-09-11 | 1970-03-24 | Mcneilab Inc | Beta-(cyclohexyl and substituted phenyl)-alpha-(4,5-dimethoxy-2-nitro- or aminophenyl) acrylonitriles |
| JPS57123181A (en) | 1981-01-23 | 1982-07-31 | Mitsubishi Paper Mills Ltd | Preparation of pyrazolo (1,5-a) pyridine derivative |
| EP0595150B1 (de) | 1992-10-29 | 1996-07-31 | Hoechst Aktiengesellschaft | Verfahren zur Herstellung von aromatischen Brommethyl-Verbindungen |
| EP0924209B1 (en) * | 1997-12-19 | 2003-05-02 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| AUPQ969800A0 (en) * | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
| JP2004525150A (ja) * | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
| CA2484631A1 (en) | 2002-05-13 | 2003-11-27 | Merck & Co., Inc. | Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles |
| WO2004041201A2 (en) | 2002-11-01 | 2004-05-21 | Viropharma Incorporated | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| TW200528459A (en) * | 2004-01-06 | 2005-09-01 | Achillion Pharmaceuticals Inc | Azabenzofuran substituted thioureas; inhibitors of viral replication |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2007069565A1 (ja) | 2005-12-12 | 2007-06-21 | Ono Pharmaceutical Co., Ltd. | 二環式複素環化合物 |
| US20100298314A1 (en) * | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| AU2008216382A1 (en) * | 2007-02-12 | 2008-08-21 | Array Biopharma, Inc. | Novel inhibitors hepatitis C virus replication |
| JP2008247878A (ja) | 2007-03-30 | 2008-10-16 | Maruishi Pharmaceutical Co Ltd | イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物 |
| GB0707000D0 (en) | 2007-04-12 | 2007-05-30 | Istituto Di Ricerche D Biolog | Antiviral agents |
| CA2714254A1 (en) | 2008-02-14 | 2009-08-20 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2009137493A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 2-substituted benzofuran compounds to treat infection with hepatitis c virus |
| WO2009137500A1 (en) | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| US7994171B2 (en) * | 2008-09-11 | 2011-08-09 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8048887B2 (en) * | 2008-09-11 | 2011-11-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2009
- 2009-08-28 US US12/549,983 patent/US8198449B2/en active Active
- 2009-09-02 CN CN200980144810.1A patent/CN102209711B/zh not_active Expired - Fee Related
- 2009-09-02 WO PCT/US2009/055648 patent/WO2010030538A2/en not_active Ceased
- 2009-09-02 MX MX2011002471A patent/MX2011002471A/es active IP Right Grant
- 2009-09-02 AU AU2009291993A patent/AU2009291993A1/en not_active Abandoned
- 2009-09-02 JP JP2011526911A patent/JP2012502099A/ja active Pending
- 2009-09-02 EP EP09792143.1A patent/EP2331502B1/en not_active Not-in-force
- 2009-09-02 KR KR1020117008086A patent/KR20110056537A/ko not_active Withdrawn
- 2009-09-02 CN CN201410060239.8A patent/CN103864783A/zh active Pending
- 2009-09-11 AR ARP090103513A patent/AR073586A1/es not_active Application Discontinuation
- 2009-09-11 TW TW098130826A patent/TW201014855A/zh unknown
-
2012
- 2012-05-14 US US13/470,727 patent/US8536338B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010030538A3 (en) | 2010-05-06 |
| CN103864783A (zh) | 2014-06-18 |
| EP2331502B1 (en) | 2016-03-02 |
| US8536338B2 (en) | 2013-09-17 |
| US20100063068A1 (en) | 2010-03-11 |
| JP2012502099A (ja) | 2012-01-26 |
| WO2010030538A2 (en) | 2010-03-18 |
| US20120232099A1 (en) | 2012-09-13 |
| MX2011002471A (es) | 2011-04-05 |
| US8198449B2 (en) | 2012-06-12 |
| CN102209711B (zh) | 2014-06-18 |
| AU2009291993A1 (en) | 2010-03-18 |
| TW201014855A (en) | 2010-04-16 |
| AR073586A1 (es) | 2010-11-17 |
| EP2331502A2 (en) | 2011-06-15 |
| CN102209711A (zh) | 2011-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20110056537A (ko) | Ｃ형 간염의 치료를 위한 화합물 | |
| JP5572725B2 (ja) | Ｃ型肝炎の処置のための化合物 | |
| US8293909B2 (en) | Compounds for the treatment of hepatitis C | |
| JP5406837B2 (ja) | Ｃ型肝炎を治療するための四環系化合物 | |
| JP5416710B2 (ja) | シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤 | |
| JP5735551B2 (ja) | Ｃ型肝炎の処置のための化合物 | |
| KR20080102161A (ko) | Ｈｃｖ ｎｓ5ｂ 억제제 | |
| BRPI0918174A2 (pt) | composto que apresenta atividade contra o vírus da hepatite c (hcv), sua composição e seu uso | |
| KR20090008344A (ko) | 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제 | |
| WO2007143521A1 (en) | Cyclopropyl fused indolobenzazepine hcv inhibitors | |
| CN102414212A (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| JP2018509401A (ja) | Ｃ型肝炎の治療のための新規化合物 | |
| KR20130008570A (ko) | Ｃ형 간염의 치료를 위한 피라졸로피리다진 유도체 | |
| CN106459070A (zh) | 用于治疗丙型肝炎的含有氰基的氮杂苯并呋喃化合物 | |
| CN101981038B (zh) | 二氧戊环和二氧戊环酮稠合的吲哚并苯并二氮杂*hcv ns5b抑制剂 | |
| EP2278977A1 (en) | Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors | |
| WO2016133970A1 (en) | Benzofurans substituted with primary benzamide as hcv inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20110408 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |